3Mills GB,Schmandt R,Gershenson D,et al.Should therapy of ovarian cancer palients be individualized based on underlying geneic defects[J].Clin Cancer Res,1999,5(9):2286-2288.
4Hannun YA.Apoptosis and dilemma of cancer chemotherapy[J].Blood,1997,89 (6):1845-1853.
5Beale PJ,Rogers P,Boxall F,et al.bcl-2 family protein expression and platinum drug resistance in ovarian carcinoma[J].Br J Can cer,2000,82 (2):436-440.
6Mano Y,Kikuchi Y,Yamamoto K,et al.Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithetlial ovarian can cer[J].Eur J Cancer.1999,35(8):1214-1219.
7Miyashita T,krajewski S,Krajewska M,et al.Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo[J].Oncogene,1994,9(6):1799-1805.
